Her2 and TGFBeta CTLs in Treatment of Her2 Positive Malignancy (HERCREEM)

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by Baylor College of Medicine
Sponsor:
Collaborators:
The Methodist Hospital System
Center for Cell and Gene Therapy, Baylor College of Medicine
Information provided by (Responsible Party):
Stephen Gottschalk, Baylor College of Medicine
ClinicalTrials.gov Identifier:
NCT00889954
First received: April 24, 2009
Last updated: July 24, 2014
Last verified: July 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: July 2030
  Estimated Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)